This double-digit growth in new drug sales showcases the company's ability to successfully commercialize cutting-edge ...

The Biden administration’s justification of the first cycle of Medicare drug price negotiations is fueling curiosity and ...

Legacy Private Trust Co. lifted its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 3.3% during the 4th quarter, ...

OXFORD, United Kingdom, Jan. 09, 2025 (GLOBE NEWSWIRE) -- (MitoRx), a platform biotechnology company developing novel ...

International Assets Investment Management LLC cut its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 98.4% ...

A novel combination for relapsed/refractory multiple myeloma produced responses in about 80% of a heavily treated population, ...

The stock's fall snapped a two-day winning streak.

The UK's self-regulated system for disclosing payments from drug companies to health care professionals and organizations is ...

New drug approved for treating chronic schizophrenia with fewer side effects. Could be beneficial for Black community.

Bristol Myers Squibb is doubling down on a partnership with Medidata, signing a multiyear agreement to continue using the ...

Licensing deals have risen in prominence in a restrained market environment. Is it desperation, or an important part of the ...

The T1D Fund, an impact investment fund that focuses on solutions to treat, prevent and cure type 1 diabetes, on Wednesday ...